X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NMD670 is a first-in-class, muscle-targeted small molecule inhibitor of the skeletal muscle specific ClC-1 chloride ion channel. It is being evaluated for the treatment of patients with generalized myasthenia gravis (gMG) who are AChR or MuSK antibody positive.
Lead Product(s): NMD670
Therapeutic Area: Immunology Product Name: NMD670
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
The proceeds will be used to complete three Phase 2 clinical studies of first-in-class ClC-1 molecule inhibitor NMD670 in myasthenia gravis, spinal muscular atrophy and Charcot-Marie-Tooth disease.
Lead Product(s): NMD670
Therapeutic Area: Genetic Disease Product Name: NMD670
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 15, 2023
Details:
NMD670 is a first-in-class small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, which is investigated for the treatmet of spinal muscular atrophy.
Lead Product(s): NMD670
Therapeutic Area: Genetic Disease Product Name: NMD670
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, and NMD Pharma’s second clinical development candidate
Lead Product(s): NMD1343
Therapeutic Area: Neurology Product Name: NMD1343
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. NMD Pharma has pre-clinically demonstrated that ClC-1 inhibition can enhance neuromuscular transmission and ultimately skeletal muscle function.
Lead Product(s): NMD670
Therapeutic Area: Genetic Disease Product Name: NMD670
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
NMD670, a small molecule inhibitor of skeletal muscle-specific ClC-1, Administration of single doses of NMD670 was associated with clinically significant improvements in Quantitative Myasthenia Gravis Score with up to 50% of patients meeting pre-specified responder criterion.
Lead Product(s): NMD670
Therapeutic Area: Immunology Product Name: NMD670
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Proceeds from the financing will be used to support the company as it progresses its lead candidate, NMD670, through completion of the ongoing Phase 2a proof-of-concept trial in patients with Myasthenia Gravis (MG).
Lead Product(s): NMD670
Therapeutic Area: Immunology Product Name: NMD670
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $39.6 million Upfront Cash: Undisclosed
Deal Type: Financing February 15, 2022
Details:
NMD670 is in development to treat the symptoms of MG and is also being evaluated for the treatment of other neuromuscular diseases.
Lead Product(s): NMD670
Therapeutic Area: Immunology Product Name: NMD670
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
Details:
NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.
Lead Product(s): NMD670
Therapeutic Area: Immunology Product Name: NMD670
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
